Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 69

1.

Increases in NMR-visible lipid and glycerophosphocholine during phenylbutyrate-induced apoptosis in human prostate cancer cells.

Milkevitch M, Shim H, Pilatus U, Pickup S, Wehrle JP, Samid D, Poptani H, Glickson JD, Delikatny EJ.

Biochim Biophys Acta. 2005 May 1;1734(1):1-12. Epub 2005 Feb 24.

PMID:
15866478
2.

Capecitabine plus paclitaxel as front-line combination therapy for metastatic breast cancer: a multicenter phase II study.

Gradishar WJ, Meza LA, Amin B, Samid D, Hill T, Chen YM, Lower EE, Marcom PK.

J Clin Oncol. 2004 Jun 15;22(12):2321-7.

PMID:
15197193
3.

Phase II study of capecitabine in patients with fluorouracil-resistant metastatic colorectal carcinoma.

Hoff PM, Pazdur R, Lassere Y, Carter S, Samid D, Polito D, Abbruzzese JL.

J Clin Oncol. 2004 Jun 1;22(11):2078-83.

PMID:
15169794
4.

Inhibition of estrogen-dependent breast cell responses with phenylacetate.

Sawatsri S, Samid D, Malkapuram S, Sidell N.

Int J Cancer. 2001 Sep 1;93(5):687-92.

5.
6.

Phenylbutyrate-induced G1 arrest and apoptosis in myeloid leukemia cells: structure-function analysis.

DiGiuseppe JA, Weng LJ, Yu KH, Fu S, Kastan MB, Samid D, Gore SD.

Leukemia. 1999 Aug;13(8):1243-53.

7.

Phenylbutyrate induces cell differentiation and modulates Epstein-Barr virus gene expression in Burkitt's lymphoma cells.

Bar-Ner M, Thibault A, Tsokos M, Magrath IT, Samid D.

Clin Cancer Res. 1999 Jun;5(6):1509-16.

8.
10.

A phase II study of 5-aza-2'deoxycytidine (decitabine) in hormone independent metastatic (D2) prostate cancer.

Thibault A, Figg WD, Bergan RC, Lush RM, Myers CE, Tompkins A, Reed E, Samid D.

Tumori. 1998 Jan-Feb;84(1):87-9.

PMID:
9619724
11.

Modulation of radiation response of human tumour cells by the differentiation inducers, phenylacetate and phenylbutyrate.

Miller AC, Whittaker T, Thibault A, Samid D.

Int J Radiat Biol. 1997 Aug;72(2):211-8.

PMID:
9269314
12.

Tumor radiosensitization based on the use of inhibitors of the mevalonate pathway of cholesterol synthesis.

Miller AC, Samid D.

Adv Exp Med Biol. 1997;400B:825-30. No abstract available.

PMID:
9547635
13.

Phenylacetate and phenylbutyrate as novel, nontoxic differentiation inducers.

Samid D, Hudgins WR, Shack S, Liu L, Prasanna P, Myers CE.

Adv Exp Med Biol. 1997;400A:501-5. Review.

PMID:
9547596
14.

Up-regulation and functional role of p21Waf1/Cip1 during growth arrest of human breast carcinoma MCF-7 cells by phenylacetate.

Gorospe M, Shack S, Guyton KZ, Samid D, Holbrook NJ.

Cell Growth Differ. 1996 Dec;7(12):1609-15.

15.

Plasma protein binding of phenylacetate and phenylbutyrate, two novel antineoplastic agents.

Boudoulas S, Lush RM, McCall NA, Samid D, Reed E, Figg WD.

Ther Drug Monit. 1996 Dec;18(6):714-20.

PMID:
8946671
16.

Transcriptional upregulation of gamma-globin by phenylbutyrate and analogous aromatic fatty acids.

Hudgins WR, Fibach E, Safaya S, Rieder RF, Miller AC, Samid D.

Biochem Pharmacol. 1996 Oct 25;52(8):1227-33.

PMID:
8937430
17.

The differentiating agent phenylacetate increases prostate-specific antigen production by prostate cancer cells.

Walls R, Thibault A, Liu L, Wood C, Kozlowski JM, Figg WD, Sampson ML, Elin RJ, Samid D.

Prostate. 1996 Sep;29(3):177-82.

PMID:
8827086
18.

Activation of a human peroxisome proliferator-activated receptor by the antitumor agent phenylacetate and its analogs.

Pineau T, Hudgins WR, Liu L, Chen LC, Sher T, Gonzalez FJ, Samid D.

Biochem Pharmacol. 1996 Aug 23;52(4):659-67.

PMID:
8759039
19.
20.

Vulnerability of multidrug-resistant tumor cells to the aromatic fatty acids phenylacetate and phenylbutyrate.

Shack S, Miller A, Liu L, Prasanna P, Thibault A, Samid D.

Clin Cancer Res. 1996 May;2(5):865-72.

21.

Phenylacetate is an inhibitor of prostatic growth and development in organ culture.

Lipschutz JH, Samid D, Cunha GR.

J Urol. 1996 May;155(5):1762-70.

PMID:
8627880
22.

Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer.

Thibault A, Samid D, Tompkins AC, Figg WD, Cooper MR, Hohl RJ, Trepel J, Liang B, Patronas N, Venzon DJ, Reed E, Myers CE.

Clin Cancer Res. 1996 Mar;2(3):483-91.

23.
24.

Functional analysis of the promoter and first intron of the human lysyl oxidase gene.

Csiszar K, Entersz I, Trackman PC, Samid D, Boyd CD.

Mol Biol Rep. 1996;23(2):97-108.

PMID:
8983023
25.
26.
27.

Inhibition of proliferation and induction of differentiation in medulloblastoma- and astrocytoma-derived cell lines with phenylacetate.

Stockhammer G, Manley GT, Johnson R, Rosenblum MK, Samid D, Lieberman FS.

J Neurosurg. 1995 Oct;83(4):672-81.

PMID:
7674018
28.
29.
30.

Cinnamic acid: a natural product with potential use in cancer intervention.

Liu L, Hudgins WR, Shack S, Yin MQ, Samid D.

Int J Cancer. 1995 Jul 28;62(3):345-50.

PMID:
7628877
31.
32.

Phase I study of phenylacetate administered twice daily to patients with cancer.

Thibault A, Samid D, Cooper MR, Figg WD, Tompkins AC, Patronas N, Headlee DJ, Kohler DR, Venzon DJ, Myers CE.

Cancer. 1995 Jun 15;75(12):2932-8.

PMID:
7773944
33.

Disposition of phenylbutyrate and its metabolites, phenylacetate and phenylacetylglutamine.

Piscitelli SC, Thibault A, Figg WD, Tompkins A, Headlee D, Lieberman R, Samid D, Myers CE.

J Clin Pharmacol. 1995 Apr;35(4):368-73.

PMID:
7650225
34.

Phenylacetate synergizes with retinoic acid in inducing the differentiation of human neuroblastoma cells.

Sidell N, Wada R, Han G, Chang B, Shack S, Moore T, Samid D.

Int J Cancer. 1995 Feb 8;60(4):507-14.

PMID:
7829265
36.

Pharmacologic activation of expression of immunodominant viral antigens: a new strategy for the treatment of Epstein-Barr-virus-associated malignancies.

Robertson KD, Barletta J, Samid D, Ambinder RF.

Curr Top Microbiol Immunol. 1995;194:145-54. No abstract available.

PMID:
7534666
37.

Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma.

Herman JG, Latif F, Weng Y, Lerman MI, Zbar B, Liu S, Samid D, Duan DS, Gnarra JR, Linehan WM, et al.

Proc Natl Acad Sci U S A. 1994 Oct 11;91(21):9700-4.

38.

Differentiation of cultured human melanoma cells induced by the aromatic fatty acids phenylacetate and phenylbutyrate.

Liu L, Shack S, Stetler-Stevenson WG, Hudgins WR, Samid D.

J Invest Dermatol. 1994 Sep;103(3):335-40.

39.

Upregulation of tumor necrosis factor-alpha production by retrovirally transduced human tumor-infiltrating lymphocytes using trans-retinoic acid.

Treisman J, Hwu P, Yannelli JR, Shafer GE, Cowherd R, Samid D, Rosenberg SA.

Cell Immunol. 1994 Jul;156(2):448-57.

PMID:
8025957
40.

Growth inhibition, tumor maturation, and extended survival in experimental brain tumors in rats treated with phenylacetate.

Ram Z, Samid D, Walbridge S, Oshiro EM, Viola JJ, Tao-Cheng JH, Shack S, Thibault A, Myers CE, Oldfield EH.

Cancer Res. 1994 Jun 1;54(11):2923-7.

41.

In vitro antitumor effect of hydroxyurea on hormone-refractory prostate cancer cells and its potentiation by phenylbutyrate.

Figg WD, Walls RG, Cooper MR, Thibault A, Sartor O, McCall NA, Myers CE, Samid D.

Anticancer Drugs. 1994 Jun;5(3):336-42.

PMID:
7919459
42.

A phase I and pharmacokinetic study of intravenous phenylacetate in patients with cancer.

Thibault A, Cooper MR, Figg WD, Venzon DJ, Sartor AO, Tompkins AC, Weinberger MS, Headlee DJ, McCall NA, Samid D, et al.

Cancer Res. 1994 Apr 1;54(7):1690-4.

43.

Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2'-deoxycytidine.

Weber J, Salgaller M, Samid D, Johnson B, Herlyn M, Lassam N, Treisman J, Rosenberg SA.

Cancer Res. 1994 Apr 1;54(7):1766-71.

44.

Selective activity of phenylacetate against malignant gliomas: resemblance to fetal brain damage in phenylketonuria.

Samid D, Ram Z, Hudgins WR, Shack S, Liu L, Walbridge S, Oldfield EH, Myers CE.

Cancer Res. 1994 Feb 15;54(4):891-5.

PMID:
8313377
45.

Differences in radiation-induced micronuclei yields of human cells: influence of ras gene expression and protein localization.

Miller AC, Gafner J, Clark EP, Samid D.

Int J Radiat Biol. 1993 Nov;64(5):547-54.

PMID:
7902394
46.

Development of a novel spontaneous metastasis model of human osteosarcoma transplanted orthotopically into bone of athymic mice.

Berlin O, Samid D, Donthineni-Rao R, Akeson W, Amiel D, Woods VL Jr.

Cancer Res. 1993 Oct 15;53(20):4890-5.

48.

Posttranscriptional down-regulation of ras oncogene expression by inhibitors of cellular glutathione.

Miller AC, Gafner J, Clark EP, Samid D.

Mol Cell Biol. 1993 Jul;13(7):4416-22.

50.

Supplemental Content

Support Center